表紙
市場調査レポート

視神経脊髄炎 (デビック病):パイプライン製品の分析

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 293889
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
視神経脊髄炎 (デビック病):パイプライン製品の分析 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 86 Pages
概要

デビック病としても知られる視神経脊髄炎 (NMO) は、脳、脊髄、神経の疾患あるいは損傷によって引き起こされる珍しい神経障害であり、自身の免疫系が異常反応し、体内の細胞や組織を攻撃してしまう自己免疫疾患です。免疫系が髄鞘を攻撃する事例もあります。症状としては、失明、脱力感、麻痺、腸および膀胱の問題などがあります。

当レポートでは、世界における視神経脊髄炎治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

視神経脊髄炎 (デビック病) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

視神経脊髄炎:開発中の治療薬:企業別

視神経脊髄炎:開発中の治療薬:大学・研究機関別

視神経脊髄炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

視神経脊髄炎:開発中の製品:企業別

視神経脊髄炎:開発中の製品:大学・研究機関別

視神経脊髄炎:治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc.
  • 中外製薬
  • Genmab A/S
  • HanAll Biopharma Co., Ltd.
  • Karus Therapeutics Limited
  • MedImmune, LLC
  • Opexa Therapeutics, Inc.
  • Shire Plc
  • 武田薬品工業

視神経脊髄炎:治療薬の評価

  • 単剤製品
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • C1エステラーゼ阻害剤 (ヒト)
  • ダルファムプリジンER
  • 中枢神経系疾患のための樹状細胞療法
  • 視神経脊髄炎のための好中球エラスターゼ阻害剤
  • エクリズマブ
  • HL-161
  • 免疫グロブリン (ヒト)
  • KA-1463
  • MEDI-551
  • オファツムマブ
  • OPX-212
  • SA-237
    • 製品概要
    • 作用機序
    • R&Dの進捗

視神経脊髄炎:最近のパイプライン動向

視神経脊髄炎:休止中のプロジェクト

視神経脊髄炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7740IDB

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2016', provides an overview of the Neuromyelitis Optica (Devic's Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)
  • The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neuromyelitis Optica (Devic's Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Neuromyelitis Optica (Devic's Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuromyelitis Optica (Devic's Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview
    • Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies
  • Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
    • Acorda Therapeutics, Inc.
    • Alexion Pharmaceuticals, Inc.
    • Bionure Farma, S.L.
    • Chugai Pharmaceutical Co., Ltd.
    • Clene Nanomedicine, Inc.
    • HanAll Biopharma Co., Ltd.
    • Karus Therapeutics Limited
    • Marathon Pharmaceuticals, LLC
    • MedImmune, LLC
    • Opexa Therapeutics, Inc.
    • Shire Plc
    • Takeda Pharmaceutical Company Limited
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANV-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNMAU-8 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • D-15107 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalfampridine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPX-212 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SA-237 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neuromyelitis Optica (Devic's Syndrome) - Recent Pipeline Updates
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
  • Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
      • Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
      • Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
      • May 08, 2015: Initiation Of Phase I Clinical Program
      • Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
      • Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
      • Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
      • Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
      • Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
      • Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2016
  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma, S.L., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Clene Nanomedicine, Inc., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Karus Therapeutics Limited, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2016
  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top